ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
298380 | KO
Overview
Corporate Details
- ISIN(s):
- KR7298380007
- LEI:
- Country:
- South Korea
- Address:
- 서울 강남구 봉은사로 456 에이비엘바이오빌딩, 강남구
- Website:
- https://www.ablbio.com
Description
ABL Bio Inc. is a clinical-stage biotechnology company specializing in the development of bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases. The company leverages several proprietary platforms. For central nervous system disorders, its 'Grabody-B' technology is a blood-brain barrier (BBB) penetrating shuttle designed to enhance drug delivery to the brain. In immuno-oncology, ABL Bio develops 4-1BB based bispecific antibodies aimed at minimizing toxicity and overcoming resistance to existing immunotherapies. The company is also advancing a pipeline of antibody-drug conjugates (ADCs) with an improved therapeutic index for conditions such as rare blood cancers. ABL Bio actively progresses its therapeutic candidates through clinical development.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-04-02 00:00 |
주식등의대량보유상황보고서(약식)
|
Korean | 54.4 KB | ||
| 2024-03-29 00:00 |
정기주주총회결과
|
Korean | 20.0 KB | ||
| 2024-03-29 00:00 |
주식매수선택권부여에관한신고
|
Korean | 15.5 KB | ||
| 2024-03-20 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 80.1 KB | ||
| 2024-03-14 00:00 |
주주총회소집결의 (정기주주총회)
|
Korean | 7.7 KB | ||
| 2024-03-14 00:00 |
주주총회집중일개최사유신고
|
Korean | 4.9 KB | ||
| 2024-03-14 00:00 |
사업보고서 (2023.12)
|
Korean | 333.9 KB | ||
| 2024-03-14 00:00 |
주주총회소집공고
|
Korean | 701.9 KB | ||
| 2024-03-14 00:00 |
의결권대리행사권유참고서류
|
Korean | 649.9 KB | ||
| 2024-03-14 00:00 |
[기재정정]사업보고서 (2023.12)
|
Korean | 1.6 MB | ||
| 2024-03-13 00:00 |
감사보고서제출
|
Korean | 25.8 KB | ||
| 2024-03-04 00:00 |
[기재정정]주식매수선택권부여에관한신고
|
Korean | 36.7 KB | ||
| 2024-02-28 00:00 |
기타시장안내 (연구개발 우수기업 매출액 특례적용 관련)
|
Korean | 2.7 KB | ||
| 2024-02-07 00:00 |
매출액또는손익구조30%(대규모법인은15%)이상변동
|
Korean | 11.6 KB | ||
| 2024-01-18 00:00 |
투자판단관련주요경영사항(임상시험계획변경승인)(이중항체 파킨슨병 치료제 ABL301의 미국 FDA 제1상 임상시험계획 (IND) 변경 승인)
|
Korean | 14.1 KB |
Automate Your Workflow. Get a real-time feed of all ABL Bio Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABL Bio Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABL Bio Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
